Customer Publication Summaries
Value of Serum Free Light Chain Testing for the Diagnosis and Monitoring of Monoclonal Gammopathies in Hematology
Sundar Jagannath, Clinical Lymphoma and Myeloma 2007 7(8):518-523
The author highlights via a review of recent literature the important role serum free light chain (FLC) assays play in the diagnosis, prognosis and monitoring of Multiple Myeloma (MM) and other monoclonal gammopathies. The publication also discusses the use of serum FLC assays in the risk stratification of monoclonal gammopathy of undetermined significance (MGUS) and plasmacytoma patients.
Click here for a complete review of this publication.
Immunoglobulin free light chain ratio is an independent risk factor for progression of smoldering (asymptomatic) multiple myeloma
Angela Dispenzieri, Blood 2008 111(2):785-789
This publication investigated whether an abnormal serum free light chain (FLC) ratio is a risk factor for progression in smoldering multiple myeloma (SMM) patients to active myeloma. This large study looked at 273 patients seen at the Mayo Clinic in the US between 1970 and 1995 and concluded an abnormal serum FLC ratio was an independent risk factor for progression in patients with SMM.
Click here for a complete review of this publication.
